Acta Scientific Clinical Case Reports

Editorial Volume 3 Issue 1

Role of Biomarkers in Neonatal and Pediatric Sepsis

Avanthika Chaithanya*

Department of Paediatrics, Karnataka Institute of Medical Sciences, India

*Corresponding Author: Avanthika Chaithanya, Department of Paediatrics, Karnataka Institute of Medical Sciences, India.

Received: November 20, 2021; Published: December 01, 2021

Sepsis is a severe public health issue that affects children all around the world. Because the treatment recommendations emphasise early detection, there is interest in identifying sepsis biomarkers, with diagnostic biomarkers receiving the greatest attention. These biomarkers can provide information on the likelihood of a poor sepsis outcome, the risk of sepsis-related organ dysfunction, and subgroups of sepsis patients that share underlying biological traits that may be susceptible to targeted therapeutics [1].

References

  1. Weiss S L., et al. “Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children”. Pediatric Critical Care Medicine 21 (2020): e52-e106.
  2. Leticia Fernandez-Carballo B., et al. “Distinguishing bacterial versus non-bacterial causes of febrile illness - a systematic review of host biomarkers”. Journal of Infection 82 (2021): 1-10.
  3. Ducharme J., et al. “A multi-mRNA host-response molecular blood test for the diagnosis and prognosis of acute infections and sepsis: proceedings from a clinical advisory panel”. Journal of Personalized Medicine 10 (2020): 266.
  4. Sampson D., et al. “Blood transcriptomic discrimination of bacterial and viral infections in the emergency department: a multi-cohort observational validation study”. BMC Medicine 18 (2020): 185.
  5. Weiss S L., et al. “Global epidemiology of pediatric severe sepsis: the sepsis prevalence, outcomes, and therapies study”. American Journal of Respiratory and Critical Care Medicine 191 (2015): 1147.
  6. Rudd K E., et al. “Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study”. Lancet 395 (2020): 200-211.
  7. Wong H R., et al. “The pediatric sepsis biomarker risk model”. Critical Care 16 (2012): R174.
  8. Wong H R., et al. “Testing the prognostic accuracy of the updated pediatric sepsis biomarker risk model”. PLoS ONE 9 (2014): e86242.
  9. Stanski N L and Wong H R. “Prognostic and predictive enrichment in sepsis”. Nature Reviews Nephrology 16 (2020): 20-31.
  10. Prescott H C., et al. “Toward smarter lumping and smarter splitting: rethinking strategies for sepsis and acute respiratory distress syndrome clinical trial design”. American Journal of Respiratory and Critical Care Medicine 194 (2016): 147-155.
  11. Fleischmann C., et al. “Global incidence and mortality of neonatal sepsis: a systematic review and meta-analysis”. Archives of Disease in Childhood 8 (2021).

Citation

Citation: Avanthika Chaithanya. “Role of Biomarkers in Neonatal and Pediatric Sepsis". Acta Scientific Clinical Case Reports 3.1 (2022): 01-02.

Copyright

Copyright: © 2022 Avanthika Chaithanya. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.278

Indexed In